Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis

被引:5
作者
Poznyak, Anastasia V. [1 ]
Sukhorukov, Vasily N. [2 ]
Eremin, Ilya I. [3 ]
Nadelyaeva, Irina I. [3 ]
Gutyrchik, Nikita A. [3 ]
Orekhov, Alexander N. [2 ]
机构
[1] Inst Atherosclerosis Res, Osennyaya 4-1-207, Moscow 121609, Russia
[2] Russian Acad Med Sci, Inst Gen Pathol & Pathophysiol, Moscow 125315, Russia
[3] Petrovsky Natl Res Ctr Surg, 2 Abrikosovsky Lane, Moscow 119991, Russia
基金
俄罗斯科学基金会;
关键词
PCSK9; atherosclerosis; cardiovascular disease; CVD; lipids; lipid metabolism; LDL RECEPTORS; CARDIOVASCULAR EVENTS; PCSK9; INHIBITION; POOLED ANALYSIS; SAFETY; CHOLESTEROL; EVOLOCUMAB; EFFICACY; DEGRADATION; ALIROCUMAB;
D O I
10.3390/biomedicines11020503
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite being the most common treatment strategy in the management of atherosclerosis and subsequent cardiovascular disease, classical statin therapy has certain disadvantages, including numerous side effects. In addition, a regimen with daily administration of the drug is hard to comply with. Thus, there is a need for modern and more efficient therapeutic strategies in CVD treatment. There is extensive evidence indicating that PCSK9 promotes atherogenesis through a variety of mechanisms. Thus, new treatment methods can be developed that prevent or alleviate atherosclerotic cardiovascular disease by targeting PCSK9. Comprehensive understanding of its atherogenic properties is a necessary precondition for the establishment of new therapeutic strategies. In this review, we will summarize the available data on the role of PCSK9 in the development and progression of atherosclerosis. In the last section, we will consider existing PCSK9 inhibitors.
引用
收藏
页数:14
相关论文
共 50 条
[41]   Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis [J].
Lu, Xinjie .
CURRENT DRUG TARGETS, 2019, 20 (10) :1029-1040
[42]   Safety and effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition: an updated review [J].
Pamporis, Konstantinos ;
Karakasis, Paschalis ;
Tsiachris, Dimitrios .
CURRENT OPINION IN LIPIDOLOGY, 2025, 36 (04) :203-210
[43]   Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis [J].
Matin, Abdul ;
Chaudhry, Gul-e-Saba ;
Azra, Mohamad Nor ;
Gazli, Mohamad ;
Sung, Yeong Yik ;
Muhammad, Tengku Sifzizul TENGku .
MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2024, 31 (04) :14-34
[44]   Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors [J].
Shahreyar, Muhammed ;
Salem, Salem A. ;
Nayyar, Mannu ;
George, Lekha K. ;
Garg, Nadish ;
Koshy, Santhosh K. G. .
JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) :628-634
[45]   The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia [J].
Tziomalos, Konstantinos .
CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (10) :1495-1499
[46]   Proprotein convertase subtilisin kexin type 9 and main artery atherosclerosis in patients with arterial hypertension [J].
Vukolova, Yulia ;
Gubareva, Irina ;
Galati, Giuseppe ;
Germanova, Olga .
MINERVA CARDIOLOGY AND ANGIOLOGY, 2023, 71 (02) :129-134
[47]   Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease [J].
Aydogan Baykara, Rabia ;
Yilmaz, Pinar Diydem ;
Goktepe, Mevlut Hakan ;
Kadiyoran, Cengiz ;
Ogul, Mustafa ;
Kucuk, Adem ;
Cumhur Cure, Medine ;
Cure, Erkan .
CLINICAL AND EXPERIMENTAL HYPERTENSION, 2022, 44 (05) :480-486
[48]   Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia [J].
Li, Bin ;
Hao, Pan-Pan ;
Zhang, Yong ;
Yin, Rui-Hong ;
Kong, Qing-Zan ;
Cai, Xiao-Jun ;
Zhao, Zhuo ;
Qi, Jian-Ni ;
Li, Ying ;
Xiao, Jie ;
Wang, Fu ;
Yi, Wei ;
Ji, Xiao-Ping ;
Su, Guo-Hai .
ONCOTARGET, 2017, 8 (18) :30455-30463
[49]   Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: Do we have a vanquishing new strategy? [J].
Veljic, Ivana ;
Polovina, Marija ;
Milinkovic, Ivan ;
Seferovic, Petar M. .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (07) :739-742
[50]   A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience [J].
Saeed, Anum ;
Virani, Salim S. ;
Jones, Peter H. ;
Nambi, Vijay ;
Zoch, Daniele ;
Ballantyne, Christie M. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (03) :596-599